3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
51 citations
,
March 2006 in “Bioorganic & Medicinal Chemistry” Newly made nicotinamide compounds could potentially treat cancer.
November 2012 in “Journal of Clinical Pathology”
May 2025 in “Birth Defects Research” YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.
8 citations
,
April 2022 in “International Journal of Environmental Research and Public Health” Most children with epilepsy on antiepileptic drugs experience side effects, especially those on multiple drugs, but these drugs help reduce seizures.
March 2019 in “Reactions Weekly”
10 citations
,
October 2017 in “Pediatric neurology” Biotin and acetazolamide improved hair and nail growth, mental function, and reduced headaches in a child with autism.
66 citations
,
February 2010 in “CrystEngComm” Made 8 minoxidil samples; 1 cocrystal, 7 salts formed.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Early diagnosis and treatment of hereditary vitamin D-resistant rickets (HVDRR) are crucial to prevent growth issues and other health problems.
2 citations
,
August 2004 Early diagnosis and proper treatment improve outcomes for methylmalonic acidemia.
5 citations
,
January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika” Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
January 2002 in “Chinese Journal of Pharmaceuticals” A new method was developed to make a compound used in finasteride and epristeride with a 69% yield.
6 citations
,
June 2013 in “Toxicological Research” Topical Valproate is safe for human skin and unlikely to cause irritation.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
13 citations
,
October 2010 in “Seizure” Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
35 citations
,
August 2004 in “Epilepsy & behavior” Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
1 citations
,
October 2019 in “Epileptic disorders” A girl with Pitt-Hopkins syndrome developed curly hair as a rare side effect from the epilepsy drug perampanel.
44 citations
,
October 2016 in “Epilepsia” 2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.
October 2007 in “Clinical Biochemistry” New genotype linked to non-classical congenital adrenal hyperplasia found in Italian siblings.
March 2025 in “Carbohydrate Polymer Technologies and Applications” The new method improves finasteride's effectiveness for hair loss treatment.
21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
1 citations
,
October 2011 in “Hospital Pharmacy”
March 2014 in “Journal of The American Academy of Dermatology” Cortexolone 17a-propionate may be an effective new treatment for hair loss.
January 2018 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” New nanocarriers were developed for safer, targeted drug delivery and diagnostics, showing promise for future medical use.